1-(2,6-difluorophenyl)-4-methylpiperazine | 1424273-39-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 1-(2,6-difluorophenyl)-4-methylpiperazine
• CAS: 1424273-39-1
• 化学式: C₁₁H₁₄F₂N₂
• 分子量: 212.242
• InChiKey: MMVRLASTUGDMAY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  6.5
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  N-甲基哌嗪 、 1,2,4-三氟苯 在 potassium carbonate 作用下， 以 N-甲基吡咯烷酮 为溶剂， 反应 1.5h， 生成 1-(2,3-difluorophenyl)-4-methylpiperazine hydrochloride 、 1-(2,6-difluorophenyl)-4-methylpiperazine
  参考文献：
  名称：

  Microwave-assisted amination from fluorobenzenes without catalyst and strong base

  摘要：

  A facile and versatile amination of fluorobenzenes has been developed in good to excellent yields under microwave irradiation in N-methylpyrrolidinone (NMP) without strong base and catalyst. The presence of additional halogen atom(s) enhanced the leaving ability of fluorine and meta fluorine gave higher activation than the ortho. It is remarkable that 1,2,3-trifluorobenzene, 1,2,4-trifluorobenzene and 1,2,4,5-tetrafluorobenzene can produce the regioselective mono-substituted products. (C) 2012 Elsevier B.V. All rights reserved.

  DOI：

  10.1016/j.jfluchem.2012.12.001

文献信息

• Imidazotriazinone or imidazopyrazinone derivatives, and use thereof
  申请人：ST PHARM CO., LTD.

  公开号：US10179785B2

  公开（公告）日：2019-01-15

  The present invention relates to a novel imidazotriazinone or imidazopyrazinone derivative, a tautomer thereof, a stereoisomer thereof and their mixture, or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition for preventing or treating a tankyrase-related disease, which contains the same as an active ingredient.

  本发明涉及一种新型咪唑三嗪酮或咪唑吡嗪酮衍生物、其同分异构体、其立体异构体及其混合物，或其药学上可接受的盐；以及一种用于预防或治疗与毒蕈碱相关疾病的药物组合物，其中含有相同的活性成分。
• [EN] 1,2,4-TRIAZOLO [4,3-A] PYRIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OR PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS<br/>[FR] DÉRIVÉS DE 1,2,3-TRIAZOLO[4,3-A]PYRIDINE ET LEUR UTILISATION POUR LE TRAITEMENT OU LA PRÉVENTION DE TROUBLES NEUROLOGIQUES ET PSYCHIATRIQUES
  申请人：ORTHO MCNEIL JANSSEN PHARM

  公开号：WO2010130424A9

  公开（公告）日：2011-01-27
• NOVEL TRIAZOLOPYRIMIDINONE OR TRIAZOLOPYRIDINONE DERIVATIVES, AND USE THEREOF
  申请人：ST Pharm Co., Ltd.

  公开号：EP3166945B1

  公开（公告）日：2019-10-09
• NOVEL IMIDAZOTRIAZINONE OR IMIDAZOPYRAZINONE DERIVATIVES, AND USE THEREOF
  申请人：ST PHARM CO., LTD.

  公开号：US20170166572A1

  公开（公告）日：2017-06-15

  The present invention relates to a novel imidazotriazinone or imidazopyrazinone derivative, a tautomer thereof, a stereoisomer thereof and their mixture, or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition for preventing or treating a tankyrase-related disease, which contains the same as an active ingredient.
• 1,2,4-Triazolo [4,3-A] Pyridine Derivatives And Their Use For The Treatment Of Prevention Of Neurological And Psychiatric Disorders
  申请人：JANSSEN PHARMACEUTICALS, INC.

  公开号：US20170333426A1

  公开（公告）日：2017-11-23

  The present invention relates to methods of treating various central nervous system disorders using novel triazolo[4,3-a]pyridine derivatives of Formula (I) wherein all radicals are as defined in the claims. The compounds according to the invention are positive allosteric modulators of the metabotropic glutamate receptor subtype 2 (“mGluR2”), which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds for the prevention or treatment of neurological and psychiatric disorders and diseases in which mGluR2 is involved.